| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1052789613 |
| P356 | DOI | 10.2165/00003495-199700544-00007 |
| P698 | PubMed publication ID | 9361959 |
| P2093 | author name string | D S Alberts | |
| D J Garcia | |||
| P2860 | cites work | Doxorubicin (adriamycin) cardiomyopathy | Q40162046 |
| Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). | Q41175631 | ||
| Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? | Q41292642 | ||
| Anthracyclines in the treatment of cancer. An overview | Q41637134 | ||
| Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours | Q41637144 | ||
| Fatal hepatic failure with liposomal doxorubicin | Q42562328 | ||
| Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. | Q45976411 | ||
| Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. | Q45994601 | ||
| A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation | Q67956981 | ||
| Lack of vesicant injury following extravasation of liposomal doxorubicin | Q71751843 | ||
| Hepatic toxicity of liposomal encapsulated doxorubicin | Q72213047 | ||
| Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma | Q33498748 | ||
| Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome | Q34710639 | ||
| Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study | Q34720336 | ||
| P921 | main subject | doxorubicin | Q18936 |
| P304 | page(s) | 30-35 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Safety aspects of pegylated liposomal doxorubicin in patients with cancer | |
| P478 | volume | 54 Suppl 4 |
| Q75307151 | A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer |
| Q34997356 | A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. |
| Q60543153 | A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer |
| Q41637134 | Anthracyclines in the treatment of cancer. An overview |
| Q37016053 | Carboplatin and Liposomal Doxorubicin for Ovarian Cancer |
| Q57291855 | Chitosan-Based Polyelectrolyte Complexes for Doxorubicin and Zoledronic Acid Combined Therapy to Overcome Multidrug Resistance |
| Q30475985 | Development and optimization of a doxorubicin loaded poly(lactic acid) contrast agent for ultrasound directed drug delivery |
| Q30461395 | Disposition of ultrasound sensitive polymeric drug carrier in a rat hepatocellular carcinoma model |
| Q44389042 | Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. |
| Q37027632 | Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery |
| Q36644505 | Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients |
| Q43687708 | Effect of cholesterol content in activation of the classical versus the alternative pathway of rat complement system induced by hydrogenated egg phosphatidylcholine-based liposomes |
| Q43969657 | Host-vs.-altered-host eruptions in patients on liposomal doxorubicin |
| Q92920924 | Immunological and Toxicological Considerations for the Design of Liposomes |
| Q35542453 | Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin |
| Q81420775 | Liposomal cytokines in the treatment of infectious diseases and cancer |
| Q34153033 | Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis |
| Q60638398 | Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate) |
| Q73867868 | Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma |
| Q89762749 | Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension |
| Q35558330 | Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone as First-Line Therapy for Multiple Myeloma |
| Q33798020 | Pegylated liposomal adriamycin: a review of current and future applications |
| Q26858830 | Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials |
| Q50719904 | Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. |
| Q34340198 | Pegylation: a novel process for modifying pharmacokinetics |
| Q30403553 | Phage protein-targeted cancer nanomedicines |
| Q34150824 | Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma |
| Q77370739 | Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial |
| Q28395046 | Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems |
| Q44325865 | Unexpected low efficacy of stealth liposomal doxorubicin (Caelyx) and vinorelbine in metastatic breast cancer |
Search more.